ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stake Increased by Natixis Advisors LLC

Natixis Advisors LLC boosted its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 2.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,601 shares of the specialty pharmaceutical company’s stock after acquiring an additional 417 shares during the period. Natixis Advisors LLC owned 0.09% of ANI Pharmaceuticals worth $1,028,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the stock. Thrivent Financial for Lutherans lifted its position in shares of ANI Pharmaceuticals by 2.3% during the third quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock worth $777,000 after purchasing an additional 299 shares during the last quarter. Exchange Traded Concepts LLC lifted its holdings in ANI Pharmaceuticals by 2.6% during the 4th quarter. Exchange Traded Concepts LLC now owns 12,366 shares of the specialty pharmaceutical company’s stock worth $684,000 after buying an additional 310 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of ANI Pharmaceuticals by 10.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company’s stock worth $246,000 after acquiring an additional 412 shares in the last quarter. US Bancorp DE increased its holdings in shares of ANI Pharmaceuticals by 842.9% in the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock valued at $33,000 after acquiring an additional 531 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of ANI Pharmaceuticals by 24.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock valued at $177,000 after acquiring an additional 579 shares in the last quarter. 76.05% of the stock is owned by institutional investors and hedge funds.

ANI Pharmaceuticals Stock Performance

ANIP stock opened at $66.33 on Wednesday. The company has a market capitalization of $1.44 billion, a P/E ratio of -120.60 and a beta of 0.63. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The company has a 50-day simple moving average of $59.88 and a 200 day simple moving average of $58.18. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.50 and a fifty-two week high of $70.31.

Insider Activity

In other ANI Pharmaceuticals news, VP Meredith Cook sold 400 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $63.33, for a total transaction of $25,332.00. Following the completion of the transaction, the vice president now directly owns 80,545 shares of the company’s stock, valued at approximately $5,100,914.85. This trade represents a 0.49 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction on Friday, March 7th. The stock was sold at an average price of $60.86, for a total value of $60,860.00. Following the completion of the sale, the senior vice president now directly owns 66,525 shares in the company, valued at $4,048,711.50. This represents a 1.48 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 3,200 shares of company stock worth $191,776 over the last three months. Corporate insiders own 12.70% of the company’s stock.

Analyst Ratings Changes

ANIP has been the subject of a number of research reports. Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th. Guggenheim boosted their price objective on shares of ANI Pharmaceuticals from $84.00 to $86.00 and gave the company a “buy” rating in a research report on Wednesday, March 5th. StockNews.com raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, March 14th. HC Wainwright reaffirmed a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, March 17th. Finally, Leerink Partners assumed coverage on ANI Pharmaceuticals in a report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price target on the stock. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, ANI Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $79.75.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.